PHAXIAM Receives Compliance Notice from Nasdaq
Read more
Newsroom
News & events
Press release
Press release
PHAXIAM Therapeutics and Vetophage Announce Strategic Research Collaboration
Read more
Press release
PHAXIAM Provides Business and Financial Update – For the First Half of 2023
Read more
Press release
PHAXIAM Therapeutics extends its phage portfolio to Klebsiella pneumoniae, a new resistant and aggressive bacterial target
Read more
Press release
PHAXIAM Therapeutics announces the completion of its reverse share split
Read more
Press release
PHAXIAM Therapeutics publishes its cash position and new financial calendar, and announces its participation at upcoming investor conferences
Read more
Press release
PHAXIAM Therapeutics announces a reverse share split of its shares
Read more
Press release
PHAXIAM Therapeutics announces its new mnemonic code on Euronext and Nasdaq: PHXM
Read more
Communiqués
ERYTECH and PHERECYDES announce merger and name change to PHAXIAM Therapeutics
Read more
Press release
ERYTECH announces the approval of the merger with Pherecydes and reports the results of the Combined Shareholder’s Meeting held on June 23, 2023
ERYTECH Pharma (Euronext Paris & Nasdaq: ERYP) announced today that all resolutions for which the Board of Directors recommended a vote in favor, including the approval of the merger with Pherecydes, were adopted by its shareholders at the Combined General Meeting that was held today, June 23, 2023
Read morePress release
ERYTECH announces that Akkadian is continuing its attempt at destabilization with the filing of a new lawsuit
ERYTECH announces that Akkadian is continuing its attempt at destabilization with the filing of a new lawsuit
Read morePress release
ERYTECH announces that the Commercial Court has rejected Akkadian’s request to postpone the vote on the merger with Pherecydes Pharma
ERYTECH announces that the Commercial Court has rejected Akkadian's request to postpone the vote on the merger with Pherecydes Pharma
Read more